[HTML][HTML] Translating the immune microenvironment of thyroid cancer into clinical practice

LL Cunha, LS Ward - Endocrine-Related Cancer, 2022 - erc.bioscientifica.com
Thyroid cancer is an excellent model for studying tumor immune microenvironment, as it
often shows local signs of an immune response. The tumor immune microenvironment of …

Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 …

I Girolami, L Pantanowitz, O Mete, M Brunelli… - Endocrine …, 2020 - Springer
The expression of programmed death-ligand 1 (PD-L1) is an established prerequisite for the
administration of checkpoint inhibitor therapy and is of prognostic value in several cancer …

[PDF][PDF] Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update

A Makker, MM Goel - Endocr Relat Cancer, 2016 - academia.edu
Endometrioid endometrial carcinoma (EEC), also known as type 1 endometrial cancer (EC),
accounts for over 70–80% of all cases that are usually associated with estrogen stimulation …

[HTML][HTML] PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications

S Ulisse, C Tuccilli, S Sorrenti, A Antonelli… - International journal of …, 2019 - mdpi.com
The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its
cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to …

PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma

MW Rosenbaum, BJ Gigliotti, SI Pai, S Parangi… - Endocrine …, 2018 - Springer
Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that
currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have …

Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis

JS Pyo, G Kang, JY Kim - The International journal of …, 2017 - journals.sagepub.com
Purpose The aim of this study was to elucidate the rates and prognostic roles of
programmed cell death ligand 1 (PD-L1) immunohistochemical (IHC) expression in various …

Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer

S Cantara, E Bertelli, R Occhini, M Regoli, L Brilli… - Endocrine, 2019 - Springer
Purpose Anaplastic thyroid carcinoma (ATC) is a rare, highly aggressive form of thyroid
cancer (TC) characterized by an aggressive behavior and poor prognosis, resulting in …

[HTML][HTML] Immune microenvironment of thyroid cancer

H Yin, Y Tang, Y Guo, S Wen - Journal of Cancer, 2020 - ncbi.nlm.nih.gov
Thyroid cancer (TC) is a highly heterogeneous endocrine malignancy with an increased
incidence in women than in men. Previous studies regarding the pathogenesis of TC …

[HTML][HTML] PD‑L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study

S Cameselle‑García… - Oncology …, 2021 - spandidos-publications.com
Anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC)
have limited treatment options, and immune profiling may help select patients for …

PD-1/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population

Y Bi, X Ren, X Bai, Y Meng, Y Luo, J Cao… - European Journal of …, 2019 - Elsevier
Introduction Few studies have focused on PD-L1 expression in medullary thyroid carcinoma
(MTC). Expressions of PD-1 and PD-L1 and their clinicopathologic and prognostic relevance …